Table 3.
Comparison of clinical characteristics between recipients with or without AKI after co-administration of azole antifungal agents
| With AKI | Without AKI | P value | |
|---|---|---|---|
| Sex | 0.613 | ||
| Male | 4 | 10 | |
| Female | 2 | 4 | |
| CYP3A5 genotypes | 0.024 | ||
| *1/*1 or *1/*3 | 0 | 8 | |
| *3/*3 | 6 | 6 | |
| Age [years, median (range)] | 60 (39–63) | 53 (37–61) | 0.353 |
| Body weight [kg, median (range)] | 55.1 (46.8–63.3) | 61.5 (48.6–75.0) | 0.097 |
| In combination with | 0.239 | ||
| Fluconazole | 4 | 11 | |
| Itraconazole | 2 | 1 | |
| Voriconazole | 0 | 2 | |
| Dose of tacrolimus (mg/day) | 2.0 (1.5–5.0) | 3.5 (3.0–4.0) | 0.659 |
| Tacrolimus C0 (ng/mL) | 16.3 (13.4–16.4) | 8.6 (6.8–9.1) | 0.020 |
AKI acute kidney injury